Repare Therapeutics
Company type: Therapeutics
Main focus: Targeted therapies that directly address the genetic alterations associated with selected tumours
Company stage: Clinical
Diseases: Multiple types of cancer
Genome-editing tool: CRISPR, to identify therapeutic targets
Funding stage: IPO (NASDAQ: RPTX)
Location: Montreal, Quebec, Canada.
Website: https://www.reparerx.com
Pipeline: https://www.reparerx.com/pipeline/
Partners: Roche, Bristol Myers Squibb
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discovering and developing novel therapeutics. The company uses its genome-wide, CRISPR-enabled, SNIPRx® platform to systematically discover and develop highly-targeted cancer therapies focused on genomic instability, including DNA damage repair.